R&D channel feed

The losers are pil­ing up af­ter to­day’s big ASH ab­stract drop

9 years ago

Spark Ther­a­peu­tics shares slide af­ter a set­back on its he­mo­phil­ia gene ther­a­py study

9 years ago

In­ves­ti­ga­tors sound a safe­ty alarm af­ter 2 pa­tients die of heart con­di­tion fol­low­ing check­point com­bo

9 years ago

Mer­ck can’t prove its Alzheimer’s drug works, yet, but it did just ex­plain why it’s spend­ing a for­tune on PhI­II

9 years ago

Se­vere ad­verse events mar the end of Roche’s PhI­II for ‘break­through’ he­mo­phil­ia drug

9 years ago

PTC sees high­er reg­u­la­to­ry risk in fight to keep its Duchenne drug on the Eu­ro­pean mar­ket

9 years ago

Buf­fet­ed by safe­ty fears, Cem­pra shares crushed af­ter FDA flags a warn­ing on its an­tibi­ot­ic

9 years ago

On­colyt­ic con­tender Turn­stone bags a $41M B round to push a suc­ces­sor for Im­ly­g­ic

9 years ago

Still pon­der­ing an M&A move, Gilead­'s R&D team out­lines a Q3 line­up of set­backs on 3 pipeline drugs

9 years ago

AveX­is shares soar af­ter it out­lines FDA’s sup­port for a loom­ing piv­otal study on SMA

9 years ago

Post-PhI­II im­plo­sion, Celldex buys on­col­o­gy drug de­vel­op­er Koll­tan in $235M deal

9 years ago

Fast biotech: Gilead hands $200M to com­pu­ta­tion­al wiz Nim­bus as it speeds in­to PhII NASH tri­al

9 years ago
Pharma

Shire prunes San­fil­ip­po A drug af­ter a failed PhI­Ib

9 years ago

Mi­croR­NA play­er Mi­Ra­gen bags $40M round and a pub­lic stock list­ing in re­verse merg­er

9 years ago

Pfiz­er dumps a fad­ing pipeline star, giv­ing up on its PC­SK9 drug bo­co­cizum­ab

9 years ago

Af­ter a se­ries of PI3k pile­ups, Genen­tech of­floads a PhII-ready ri­val for fire­sale price

9 years ago
Pharma

Man­u­fac­tur­ing woes de­rail a block­buster con­tender from Sanofi/Re­gen­eron. Who's next?

9 years ago

On the ropes, Opexa shares blast­ed by PhI­Ib mul­ti­ple scle­ro­sis tri­al flop

9 years ago

In­dus­try vet Ken Moch jumps to the helm of a small biotech with big dreams for treat­ing Alzheimer’s

9 years ago

Bil­lion­aire Be­zos, Arch car­ry a torch for ag­ing R&D, back $116M mega-round for Uni­ty

9 years ago

FDA slaps a par­tial hold on one of As­traZeneca's cru­cial dur­val­um­ab pro­grams

9 years ago

Pro­QR shares spike on pos­i­tive PoC study for lead CF drug

9 years ago

Bruised by a pun­ish­ing Op­di­vo fail­ure, Bris­tol-My­ers looks to shake up the busi­ness, ac­cel­er­ate R&D

9 years ago

Glax­o­SmithK­line sounds taps for a once-mighty R&D pro­gram

9 years ago
First page Previous page 313314315316317318319 Next page Last page
A service from the Financial Times